GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Nurexone Biologic NRX.V · CAD

N/A · TSX Venture · 🇨🇦 Canada

Compare

0.50

0.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Nurexone Biologic

Its shares trade on TSX Venture under the ticker NRX.V. It has been listed since 8 May 2012.

NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles (EV)-based technology drug platform. The company is headquartered in Edmonton, Alberta. The company went IPO on 2012-05-08. The firm is developing and commercializing an exosome therapy ExoTherapy production platform and products for a global market. The company is involved in the development of ExoPTEN, the first ExoTherapy-based product for acute Spinal Cord Injuries (SCI). The firm is developing treatment for the reversal or reduction of paralysis following spinal cord injury (SCI) using Exosomes (membrane-bound extracellular vesicles). This technology, subject to conducting clinical trials and receiving Food and Drug Administration (the FDA) approval, can be used in various conditions such as SCI, Brain Trauma Injury (BTI), and potentially other brain and neurological indications.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
N/A
Industry
N/A
Listed since
8 May 2012
Employees
8

Leadership

Pay as last reported

  • Mr. James RichardsonChairman of the Board, Chief Executive OfficerC$54,000
  • Mr. John ArnoldChief Financial Officer, Corporate Secretary, Director, since 2015C$18,000
  • Mr. John-Peter BradfordDirector
  • Mr. Peter AndrewsIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Developing ExoPTEN for acute Spinal Cord Injuries with FDA approval potential.
  • ExoTherapy platform for global market expansion in neurological treatments.
  • 8 full-time employees focused on biologic extracellular vesicles technology.

Weaknesses

  • Only 8 employees limit scalability and resource allocation.
  • IPO in 2012 with limited market presence since then.
  • Dependent on FDA approval for ExoPTEN commercialization.

Opportunities

  • Global market for neurological treatments including SCI and BTI conditions.
  • Expansion into other brain and neurological indications beyond SCI.
  • Growing interest in exosome therapies for medical applications.

Threats

  • FDA approval delays could hinder ExoPTEN launch timeline.
  • Competition in neurological treatment market remains unverified.
  • Regulatory hurdles in multiple countries for global expansion.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.